Cardiologist and Medical Director, Dr. Kereiakes discusses Elixir Medical’s Bioadaptor Device for heart patients. Elixir's Bioadaptor device will save millions of heart disease patients over the next few decades. Unlike stents, the novel scaffolding design of this med-tech device affords a heart patient's arteries a chance to recover to the tune of 90% back to its original form. By comparison, those who receive stents, need more stents to thwart future blockages caused by the primary stent application. In ten years, the survival rate for those with a stent is generally not optimistic.
EP 1,267B - The Next Generation of Stents: A New Era in Heart Treatment
Featured Speaker:
Dr. Dean Kereiakes, MD
Dr. Dean Kereiakes, Chairman and Medical Director of The Christ Hospital Heart and Vascular Institute in Cincinnati, and the scientific advisor for Elixir Medical. In addition to being a leading scientist, researcher, innovator, author, and administrator, he is a world-renowned physician who has led many clinical trials and was the main author in many publications.
He is also the leader and co-primary investigator of the upcoming FDA approval trial for Elixir Medical’s DynamX Bioadaptor, a device that’s designed to restore natural vessel function. Unlike rigid stents, the bioadaptor unlocks over time, allowing arteries to regain nearly 100% of their natural movement within just a few years.